Articles related to PERIOPERATIVE CARE

“In a prospective study of 118 patients undergoing coronary catheterization with IVUS, the presence of alpha-gal–specific IgE was associated with significantly greater atheroma burden and high-risk plaque morphology, including increased calcification, fibrofatty content and necrotic core volume.”

Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.

The analysis demonstrates that periprocedural bleeding rates with factor XI inhibition were comparable to or lower than traditional anticoagulation, with only 0.9% of procedures within 30 days of abelacimab dosing experiencing major bleeding complications.

In this randomized trial of 1,010 patients with stable DES undergoing noncardiac surgery, perioperative aspirin continuation showed no significant reduction in major adverse cardiac events compared to complete antiplatelet cessation.

The 2024 guideline introduces a more nuanced approach to preoperative stress testing and anticoagulation management, potentially reducing unnecessary testing and complications.